Article Text

Download PDFPDF

5PSQ-116 Persistence of inhibitors of interleukin-23 (anti-IL-23) for the treatment of moderate-to-severe psoriasis (msPs) in the routine clinical practice conditions
  1. L Domínguez Senín1,
  2. S Camacho Parreño2,
  3. E Sánchez Gómez2,
  4. M Rodriguez Jorge2,
  5. MD Santos-Rubio2
  1. 1Hospital Juan Ramón Jimenez, Hospital Pharmacy, Huelva, Spain
  2. 2Hospital Juan Ramón Jiménez, Hospital Pharmacy, Huelva, Spain


Background and Importance Anti-IL-23 have emerged as safe and effective options for the treatment of msPs.

Aim and Objectives We aimed to evaluate the persistence of anti-IL-23 (guselkumab and risankizumab) in patients with msPs. Secondarily, these patients’ clinical outcomes and health-related quality of life (HRQL) and the safety profile were also assessed.

Material and Methods Retrospective observational study from January 2019 to September 2022. Patients with msPs receiving anti-IL-23 were included. Demographic (sex, age) and clinical data (previous biological treatments, therapy duration and baseline Psoriasis Area and Severity Index (PASI)) were collected from the digital medical record. Non-persistence was defined as treatment discontinuation or a treatment gap > 90 days. The cumulative probability of treatment persistence was analysed by Kaplan-Meier method. Secondary endpoint: PASI90 response at 1 year, change in HRQL through dermatology life quality index (DLQI) at 1 year, and safety profile.

Results 44 patients were included (26 women), 30 received guselkumab and 14 risankizumab. Mean age was 53.5 years. 93.2% received biologic therapies before, and 86.3% conventional systemic treatment. At data cut-off time, 73.3% and 92.8% patients remained on guselkumab and risankizumab respectively. The main cause of discontinuation was primary failure. In 13.3% of guselkumab patients, dose interval was extended >8weeks and in 7.1% of risankizumab patients was extended >12 weeks. The cumulative probability of guselkumab treatment persistence was 79.7% at 1 year and for risankizumab 92.6%. The median PASI score was 8 and 9 at guselkumab and risankizumab treatment initiation respectively. 50% of guselkumab patients and 64.3% of risankizumab patients achieved PASI90 improvement at 1 year. 44.8% of guselkumab and 71.4% of risankizumab patients achieved a minimal clinically significant difference (>4-point reduction) in DLQI score at 1 year. One patient experienced one adverse reaction (ARs) related to guselkumab: headache and two risankizumab patients experienced increase in transaminases.

Conclusion and Relevance Our cohort shows a moderate persistence rate and PASI improvement at 1 year with guselkumab and a moderate benefit in improving HRQL. High persistence rate and moderate PASI improvement was reached with Risankizumab and a substantial improvement in HQRL. No important adverse reactions were found, without treatment withdrawals.

Conflict of Interest No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.